PBSC products for auto-and allografting can be cryopreserved in liquid nitrogen with controlled-rate freezing until their use. Alternatively, they can be stored at − 80°C in a mechanical chest freezer, but it remains to be clarified whether PBSCs can be stored for the long term. We evaluated viability and functions of PBSCs cryopreserved for more than 10 years with this simplified method. Although recovery rate and viability of CD34 + cells were significantly decreased, myeloid differentiation potential and in vivo reconstitution and self-renewal potential of CD34 + cells in a xenogeneic engraftment assay were maintained for more than 10 years. These results indicate that PBSCs can be stored at − 80°C for years. Although accumulation of clinical engraftment data is required to confirm our results, this simplified cryopreservation will thus meet the increasing worldwide demand for PBSC transplantation in a region with limited resources.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has been widely performed in the treatment of various malignant and nonmalignant diseases involving the hematopoietic system. PBSCs are the most widely used stem cell source for both allogeneic and autologous transplantation. 1 PBSC products often need to be stored for several days to months or even years, depending on the disease status and treatment schedule.
Cellular therapy products are usually cryopreserved in a programmable controlled rate freezer at liquid-or vapor-phase nitrogen temperature (⩽ −180°C) until their use. 2 An alternative simplified method for cryopreservation in ⩽ − 70°C mechanical freezer without rate-controlled freezing was initially developed by Stiff et al. 3 in 1983. This method was originally developed to store unfractionated bone marrow cells in a cryoprotectant consisting of 6% hydroxyethylstarch and 5% DMSO. 3 Makino et al. 4 extended this method to cryopreserve PBSCT.
Engraftment after PBSCT is highly dependent on CD34 + cell numbers infused. Several studies reported that viability of colonyforming units (CFUs) and CD34 + cells did not decrease after longterm (LT) storage and was comparable to controlled-rate freezing and storage in liquid nitrogen. [4] [5] [6] [7] [8] However, limitations of these studies includes relatively short periods of storage, evaluation using small aliquot cryovials and lack of functional assays of stem cells. Therefore, a guideline issued by the Worldwide Network for Blood and Marrow Transplantation recommends storing cellular therapy products in liquid-or vapor-phase nitrogen for LT storage for years and limits cryopreservation in a mechanical chest freezer for shorter-term cryopreservation for months. 2 In this study, we evaluated the recovery and functions of hematopoietic stem cells and their progeny, and immunologic functions of T, B and natural killer (NK) cells in PBSC products cryopreserved in a bag, not small aliquots, for more than 10 years.
MATERIALS AND METHODS Patients
PBSCs collected from 12 patients with hematologic malignancies for autografting were evaluated in this study. All the patients died before use of these stored autologous PBSCs. This study was approved by the institutional review board (No. 26-277). Patient characteristics are shown in Table 1 . Short-term (ST) and LT storage was defined as cryopreservation time o6 months and 410 years, respectively.
Harvest and cryopreservation of PBSCs
PBSCs were collected by apheresis from patients with hematologic malignancies in remission during hematologic recovery from chemotherapy with G-CSF, as previously described, using a COBE Spectra (TerumoBCT, Tokyo, Japan). 9 Collected cells were gently mixed with an equal volume of cryoprotective solution CP-1 (Kyokuto Pharmaceutical Industrial Co. Ltd, Tokyo, Japan,) consisting of 12% hydroxyethylstarch and 10% DMSO. Cells were stored in a mechanical chest freezer at − 80°C without rate-controlled freezing as described. 4 Flow cytometric analysis and cell sorting PBSC products were taken from the freezer and immediately placed in a 37°C water bath until ice crystals disappeared. Cells were then washed and resuspended in PBS. Total nucleated cells (TNCs) were counted by using an automated hematology analyzer KX-21 (Sysmex, Kobe, Japan) or ABX Pentra hematology analyzer (Horiba, Kyoto, Japan). Cell viability was determined by 7-amino-actinomycin D staining (BD Biosciences, Japan, Tokyo). Monoclonal Abs used were FITC-, phycoerythrin-or APC-conjugated CD3, CD4, CD8, CD14, CD19, CD20, CD33, CD34, CD38, CD45 and CD56, as well as a Cy5-, phycoerythrin-or PC5-conjugated lineage cocktail, including CD3, CD4, CD8, CD10, CD11b, CD14, CD19, CD20, CD56 and GPA. All monoclonal Abs were purchased from BD Biosciences. Isotype-matched irrelevant control antibodies were used to determine the level of background staining. Analysis and cell sorting were performed by a FACSAria III and an automatic cell-deposition unit system (BD Biosciences, Japan) as described previously. 10 Data were analyzed using a FlowJo software (Tree Star Inc., Ashland, OR, USA).
CFU assays
CFU assays were performed using a methylcellulose culture system that was set up to detect all the possible previously reported outcomes of myeloid differentiation. 10 In brief, the sorted CD34 + cells (100 cells per plate) were cultured in Methocult H4100 (StemCell Technologies, Vancouver, BC, Canada) supplemented with 20% FCS, 1% BSA, 2 mM L-glutamine, 50 mM 2-ME and antibiotics in the presence of human cytokines such as interleukin-3 (20 ng/mL), stem cell factor (20 ng/mL), Flt3 ligand (20 ng/mL), TPO (50 ng/mL), EPO (4 U/mL) and G-/M-CSF (50 ng/mL) in triplicate. All the cytokines were obtained from R&D Systems (Minneapolis, MN, USA). The colonies were enumerated after 14 days of culture under 5% CO 2 at 37°C in a humidified chamber. All single colonies were picked up and mounted on cytospin preparations to define the cell components. 10 Xenogeneic mouse model Purified CD34 + cells (5.0 × 10 4 cells per mouse) were IV injected into 6-to 8-week-old female non-obese diabetic (NOD)/SCID mice (Charles River Laboratory Japan, Yokohama, Japan) following 2.4 Gy radiation as described. 10 Carboxyfluorescein succinimidyl ester assay Carboxyfluorescein succinimidyl ester assay to evaluate the T-cell function was performed by using CSFE Cell Division Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) and Dynabeads Human T-Expander CD3/CD28 (Life Technologies Corporation, Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, CD3 + T cells isolated from PBSCs were labeled with carboxyfluorescein succinimidyl ester and cocultured with CD3/CD28 stimuli for 3-5 days.
11 T-cell proliferation capacity was analyzed by evaluating the proportion of dividing cells by a FACSAria III.
Evaluation of B-cell function B-cell activation was evaluated by the production of interleukin-10 (R&D Systems) after stimulation by Ig. In short, the sorted B cells were cultured in RPMI-1640 (Life Technologies Corporation) supplemented with 10% FCS in the presence of 20 μg/mL of anti-human Ig (MP Biomedicals, Japan, Tokyo) in a 96-well flat-bottom plate (1 × 10 5 cells per well) for 36 h of culture under 5% CO 2 at 37°C in a humidified chamber. mRNAs were then extracted from cells and reverse transcribed to cDNA as described previously. 12 The mRNA levels were quantified in triplicate using a real-time PCR (Applied Biosystems, Japan, Tokyo). β2-Microglobulin mRNA separately amplified in the same plate was used for internal control. The primer and probes for these mRNAs were purchased from Applied Biosystems.
Calcein-release assay for NK cell
Calcein-release assay was performed with suspension target cells as described previously. 13 In brief, the K562 cells were labeled by calcein AM (Life Technologies Corporation) under 5% CO 2 at 37°C in a humidified chamber for 45 min. Hundred microliters of each labeled K562 cells (1 × 10 5 cells per mL) and sorted CD3 − CD56 + NK cells (1 × 10 6 cells per mL) was mixed and dispensed into a 96-well plate and incubated under 5% CO 2 at 37°C in a humidified chamber for 4 h. Supernatants were collected and these fluorescence intensities were evaluated. The cytolytic activities of NK cells were estimated by the proportion of (mean max − mean blank) to (mean experiment − mean blank).
Sterility test
The sterility test was conducted according to the instructions of 'The Japanese Pharmacopoeia' 16th edition.
Statistical analysis
The significance of the differences between groups was determined using the Mann-Whitney U-test. A P-value o0.05 was considered statistically significant.
RESULTS

Recovery and viability of LT cryopreserved cells after thawing
We evaluated cell recovery and viability after thawing of LT and ST cryopreserved cells. The average preservation term of eight LT samples was 137.4 months, whereas that of four ST samples was 4.6 months ( Table 1) . Recovery rates of TNCs were equivalent between the LT and ST cells (82.9% vs 96.3%, P = 0.28), whereas those of CD34 + cells were significantly less in the LT cells compared with that in the ST cells (70.1% vs 92.6%, P = 0.05). Viability of both TNCs (61.9% vs 90.9%, P = 0.02) and CD34 + cells (72.6% vs 96.2%, P = 0.02) determined by 7-amino-actinomycin D staining was significantly less in the LT cells compared with that in the ST cells. Viability of CD3 + T cells was also significantly less in the LT cells compared with that in the ST cells (53.7% vs 91.4%, P = 0.02). Abbreviations: HD = Hodgkin's disease; LT = long term; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma; ST = short term; TNC = total nucleated cell. *Po0.05.
Long
To evaluate whether LT cryopreservation impaired the myeloid differentiation capacity of PBSCs, the lineage-affiliated Agnegative (Lin − ) CD34 + population was sorted from the ST and LT cells. A total of 100 cells were sorted and then plated in methylcellulose cultures with the cytokine cocktails as described in the Materials and methods section. The Lin − CD34 + cells gave rise to various types of myeloid colonies including mixed colonies, CFU-macrophage, CFU-granulocyte, CFU-granulocyte/macrophage, CFU-megakaryocyte/erythroid, CFU-megakaryocyte and burst-forming units erythroid. The differentiation potential of CD34 + cells isolated in the LT cells was equivalent to those cells in the ST cells (Figure 1 Figure 2a) . Furthermore, there was no difference in lymphoid and myeloid engraftment between these cells (Figure 2b) . To evaluate the self-renewal ability of the LT samples, the serial transplantation experiments were performed. Human CD45 + cells were purified from the primary recipient mice and 1 × 10 6 cells were transplanted into sublethally irradiated secondary NOD/SCID recipients. Donor chimerism of human CD45 + cells in the bone marrow 3 months after the second transplantation was again equivalent between the ST and LT cells (Figure 2c ). There was also no difference in lymphoid and myeloid engraftment in the secondary recipient mice between these cells (Figure 2c) . Collectively, these data indicated that the in vivo reconstitution and self-renewal potentials were maintained after LT cryopreservation at − 80°C.
Functional analysis of LT cryopreserved T, B and NK cells
We also evaluated whether immunological functions of T, B and NK cells could be maintained during LT cryopreservation at − 80°C in vitro. CD3 + T-cell proliferative response to CD3/CD28 stimulation was equivalent between the LT and ST cells (Figure 3a) . B-cell function determined by interleukin-10 mRNA expression in response to Ig stimulation was also equivalent between the LT and ST cells (Figure 3b ). NK cell function was evaluated by calceinrelease assay. As shown in Figure 3c , cytolytic activity of NK cells in the LT cells was similar to that in the ST cells (36.4% vs 40.5%, P = 0.53). These data indicate that the T, B and NK cell functions are maintained during LT cryopreservation at − 80°C.
Sterility
We examined the sterility of the LT cells. The test proved that all of the eight LT samples were negative for at least typical infectious agents such as Staphylococcus species, Escherichia coli, Bacillus species, Pseudomonas species, Clostridium species, Salmonella species, Candida species and Aspergillus species. DISCUSSION G-CSF-mobilized PBSCs are a widely used HSC source for both allogeneic and autologous HSCT for the treatment of various hematological malignancies. 1 Cellular therapy products such as PBSCs may need to be cryopreserved until their use. There are two major methods of cell cryopreservation: controlled rate freezing and storage in liquid-or vapor-phase nitrogen at ⩽ − 180°C and uncontrolled freezing at ⩽ − 70°C. The former method is recommended for longer-term storage for years because the latter method lacks sufficient evidence of its safety. 2 In this study, we have shown that although viability of CD34 + cells significantly decreases with LT storage, abilities of CD34 + cells to differentiate and reconstitute hematopoiesis in a xenogeneic model were not significantly different with ST and LT storage at − 80°C.
There are several studies on the cell recovery of PBSC or BM products after LT cryopreservation in liquid nitrogen using rate-controlled freezing. Fernyhough et al.
14 demonstrated that recovery of total cells and CD34 + cells from PBSC and BM products stored for 11-18 years significantly declined with time. Liseth et al. 15 showed that viability of CD34 + cells decreased to 73% after 5 years of cryopreservation in liquid nitrogen. However, the speed of engraftment after autologous PBSCs was almost equivalent in myeloma patients who received the second autologous PBSCT between the first PBSCT using a median of 1.5 month cryopreserved PBSC products and the second PBSCT using a median of 42 month cryopreserved PBSC products, suggesting that such a CD34 + cell loss does not have any major impact on the safety of PBSCT. 15 On the other hand, Abbruzzese et al. 16 reported that viability of CD34 + cells was equivalent after 5 weeks and 9-10 years of cryopreservation. Clinical data also indicate that engraftment is not delayed in patients after autologous PBSCT using cryopreserved PBSCs for 3-9 years. [15] [16] [17] Regarding uncontrolled freezing and storage at − 80°C, several studies have shown that ST storage for months to several years does not decrease viability of CD34 + cells or colony-forming cells. 5, 7, [18] [19] [20] However, few studies have addressed effects of LT storage of PBSC products. Costa et al. 17 reported that viability of TNCs was around 80% and not changed with storage time up to 14 years. Engraftment was rapid in two patients who received autologous PBSCT stored for 8-9 years at − 80°C. Other studies also showed rapid and sustained engraftment after autologous PBSCT stored at − 80°C with the simplified method for several months to years. 18, 19, 21 McCullough et al. 7 compared the impacts of LT storage of PBSCs up to 5 years between the two cryopreservation methods; viability and recovery of CD34 + cells were comparable. Our study confirms and extends these studies by evaluating recovery rates of CD34 + cells and their functions including differentiation, reconstitution and self-renewal after more than 10 years cryopreservation at − 80°C.
Our study demonstrated that recovery rate and viability of CD34 + cells was 70% and 73%, respectively, after 10-12 years of cryopreservation. Thus, it seems that our results are intermediate between results from recent two studies: 96% recovery after 9-10 years 16 and 55% recovery after 10-12 years cryopreservation in liquid nitrogen.
14 However, in our study, the number of samples is relatively small and there is wider variability in results in the LT storage group versus the ST group. This is probably because of the small numbers of samples since time-dependent increase in variability of cell viability was not reported. 5, 14, 17 Taken together, the quality of PBSC products appears to decline after 10 years of cryopreservation, irrespective of method of cryopreservation. Such an eventual loss of CD34 + cells should be taken into consideration before the use of LT cryopreserved PBSCs, as engraftment depends largely on CD34 + cell yields in both autologous and allogeneic PBSCT.
Limitations of previous studies include the relatively short periods of storage, use of aliquot vials for testing and the absence of engraftment study. The impact of LT cryopreservation is mostly estimated by measuring cell viability in aliquot vials of the PBSC products, but cell viability may differ between aliquot vials and actual bags used for cryopreservation of PBSC products. Our study directly measuring effects of LT storage in bags is thus more relevant than other previous studies using cryovials.
Most of the previous studies also estimated function of stem cells by measuring viability of CD34 + cells. Engraftment is the ultimate in vivo test of the function of cryopreserved stem cells. Viability is usually measured by nuclear dye exclusion; however, this method only detects latest stages of cell death. In addition, freezing and thawing could induce functional impairment of the live cells. Thus, functional assays of the live cells after thawing provide important information about the quality of the cellular therapy products. In this study, we directly assessed function of CD34 + hematopoietic stem cells and their progeny by measuring myeloid differentiation potential in vitro and in vivo reconstitution and self-renewal ability in a xenogeneic engraftment assay. Our results indicate that differentiation, reconstitution and selfrenewal ability of CD34 + cells are maintained in − 80°C for more than 10 years. It has been suggested that CD34 + cells may be less vulnerable to cryopreservation stress by LT cryopreservation than lineage committed cells. 16 Few studies analyzed immune recovery after autologous PBSCT with the simplified cryopreservation method. We investigated effects of LT cryopreservation using hydroxyethylstarch and DMSO in − 80°C on functions of lymphoid cells. LT storage in mechanical freezer without rate-controlled freezing at − 80°C did not impair immunologic functions of T, B and NK cells for more than 10 years. Thus, LT cryopreservation at − 80°C for 10 years did not result in impairment of immunologic recovery or reduction of GVHD or GvL effect after HSCT. However, viability of T cells was significantly reduced after LT culture and such a quantitative T-cell loss should be considered in the case of T-cell therapy.
Our study supports recent studies suggesting that cellular therapy products can be stored using mechanical freezing at − 80°C. 7, [17] [18] [19] [20] The mechanical freezing method at − 80°C provides technical simplification and cost reduction, and therefore supports a hematopoietic stem cell transplant program in countries with limited resources in startup conditions as an alternative to liquid nitrogen storage, but requires a constant and reliable electrical power supply. However, our results need to be confirmed by clinical engraftment data or in future prospective studies to compare viability and recovery between bags cryopreserved at − 80°C or in liquid nitrogen from the same donors.
